Killing SCLC: insights into how to target a shapeshifting tumor
- Author(s)
- Sutherland, KD; Ireland, AS; Oliver, TG;
- Details
- Publication Year 2022-03-01,Volume 36,Issue #5-6,Page 241-258
- Journal Title
- Genes & Development
- Abstract
- Small cell lung cancer (SCLC) is a rapidly growing, highly metastatic, and relatively immune-cold lung cancer subtype. Historically viewed in the laboratory and clinic as a single disease, new discoveries suggest that SCLC comprises multiple molecular subsets. Expression of MYC family members and lineage-related transcription factors ASCL1, NEUROD1, and POU2F3 (and, in some studies, YAP1) define unique molecular states that have been associated with distinct responses to a variety of therapies. However, SCLC tumors exhibit a high degree of intratumoral heterogeneity, with recent studies suggesting the existence of tumor cell plasticity and phenotypic switching between subtype states. While SCLC plasticity is correlated with, and likely drives, therapeutic resistance, the mechanisms underlying this plasticity are still largely unknown. Subtype states are also associated with immune-related gene expression, which likely impacts response to immune checkpoint blockade and may reveal novel targets for alternative immunotherapeutic approaches. In this review, we synthesize recent discoveries on the mechanisms of SCLC plasticity and how these processes may impinge on antitumor immunity.
- Publisher
- CSHP
- Keywords
- heterogeneity; lung cancer; neuroendocrine; plasticity; small cell
- Research Division(s)
- Cancer Biology And Stem Cells
- PubMed ID
- 35318269
- Publisher's Version
- https://doi.org/10.1101/gad.349359.122
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-03-25 10:46:23
Last Modified: 2024-06-27 11:35:04